Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
SMMT reports ivonescimab monotherapy showed a statistically significant overall survival benefit versus pembrolizumab monotherapy in PD-L1-positive advanced NSCLC in the HARMONi-2 study.
Summit Therapeutics said Akeso announced positive overall survival results from the Phase III HARMONi-2 randomized, double-blind study comparing ivonescimab and pembrolizumab monotherapy in PD-L1-positive advanced NSCLC.